SMAR
SMARTSHEET INC
No data for this timeframe.
Vol
Inst. Holders10 funds
Inst. Value$1.5B
Inst. Activity0 buys / 10 sells
Recent Activity
Inst.
VANGUARD GROUP INC — EXIT
0 shares ($0.00)
Inst.
FMR LLC — EXIT
0 shares ($0.00)
Analyst Ratings
2Strong Buy
4Buy
17Hold
0Sell
0Strong Sell
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $797.6M | EXIT |
| UBS Group AG | $437.5M | EXIT |
| RENAISSANCE TECHNOLOGIES LLC | $113.5M | EXIT |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $71.9M | EXIT |
| MORGAN STANLEY | $49.6M | EXIT |
10 institutional holders with $1.5B total value (27,115,716 shares) as of 2024-Q4. Top holders: VANGUARD, UBS, RENAISSANCE. Net selling activity: 3 institutions trimmed/exited vs 2 added.
Top Institutional Holders — 2024-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 14,235,855 | $797.6M | 52.5% | EXIT -100.0% |
| 2 | UBS Group AG | 7,809,022 | $437.5M | 28.8% | EXIT -100.0% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 2,026,505 | $113.5M | 7.5% | EXIT -100.0% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,282,883 | $71.9M | 4.7% | EXIT -100.0% |
| 5 | MORGAN STANLEY | 884,567 | $49.6M | 3.3% | EXIT -100.0% |
| 6 | NORGES BANK | 458,005 | $25.7M | 1.7% | EXIT -100.0% |
| 7 | CITADEL ADVISORS LLC | 371,246 | $20.8M | 1.4% | EXIT -100.0% |
| 8 | TWO SIGMA INVESTMENTS, LP | 16,910 | $947.5K | 0.1% | EXIT -100.0% |
| 9 | WELLS FARGO & COMPANY/MN | 16,752 | $938.6K | 0.1% | EXIT -100.0% |
| 10 | FMR LLC | 13,971 | $782.8K | 0.1% | EXIT -100.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | EXIT | 14,235,855 | 0 | -100.0% | $0.00 | 2025-Q1 |
| FMR LLC | EXIT | 13,971 | 0 | -100.0% | $0.00 | 2025-Q1 |
| MORGAN STANLEY | EXIT | 884,567 | 0 | -100.0% | $0.00 | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | EXIT | 16,752 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | 1,282,883 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | EXIT | 7,809,022 | 0 | -100.0% | $0.00 | 2025-Q1 |
| NORGES BANK | EXIT | 458,005 | 0 | -100.0% | $0.00 | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 2,026,505 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | EXIT | 371,246 | 0 | -100.0% | $0.00 | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 16,910 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 181,954 | 7,809,022 | +4191.8% | $437.5M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 788,205 | 2,026,505 | +157.1% | $113.5M | 2024-Q4 |
| MORGAN STANLEY | TRIM | 1,499,173 | 884,567 | -41.0% | $49.6M | 2024-Q4 |
| CITADEL ADVISORS LLC | TRIM | 786,826 | 371,246 | -52.8% | $20.8M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 34,135 | 16,752 | -50.9% | $938.6K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 1,278,665 | — | $70.8M | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 26% buy across 23 analysts — 2 strong buy, 4 buy, 17 hold, 0 sell, 0 strong sell. No current recommendation available.
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Mar 1, 2025 | 2 | 4 | 17 | 0 | 0 | 26% | |
| Feb 1, 2025 | 2 | 4 | 17 | 0 | 0 | 26% | |
| Jan 1, 2025 | 2 | 4 | 17 | 0 | 0 | 26% | |
| Dec 1, 2024 | 2 | 4 | 17 | 0 | 0 | 26% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.